-
1
-
-
84867035474
-
Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience
-
Abstract 294
-
Alejandro LM, Adel NG, O'Reilly EM, Riedel E, Lacouture ME (2012) Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol 30: Abstract 294.
-
(2012)
J Clin Oncol
, vol.30
-
-
Alejandro, L.M.1
Adel, N.G.2
O'reilly, E.M.3
Riedel, E.4
Lacouture, M.E.5
-
2
-
-
10844264628
-
An epidermal growth factor receptor intro 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
-
Amador MR, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M (2004) An epidermal growth factor receptor intro 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64: 9139-9143.
-
(2004)
Cancer Res
, vol.64
, pp. 9139-9143
-
-
Amador, M.R.1
Oppenheimer, D.2
Perea, S.3
Maitra, A.4
Cusatis, G.5
Iacobuzio-Donahue, C.6
Baker, S.D.7
Ashfaq, R.8
Takimoto, C.9
Forastiere, A.10
Hidalgo, M.11
-
3
-
-
84864307160
-
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: Relationship between skin rash and survival (Pantar study)
-
Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Diaz-Rubio E (2012) Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol 23: 1919-1925.
-
(2012)
Ann Oncol
, vol.23
, pp. 1919-1925
-
-
Aranda, E.1
Manzano, J.L.2
Rivera, F.3
Galan, M.4
Valladares-Ayerbes, M.5
Pericay, C.6
Safont, M.J.7
Mendez, M.J.8
Irigoyen, A.9
Arrivi, A.10
Sastre, J.11
Diaz-Rubio, E.12
-
4
-
-
84920681430
-
Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study
-
Abstract 7542
-
Buges C, Marti AM, Rosell R, Vergnenegre A, De Marinis F, Massuti B, De Castro J, Gervais R, Costa EC, Moran T, Santarpia M, Felip E, Majem M, Porta R, Palmero R, Drozdowskyj A, Heidecke C, Gasco A, Taron M, Paz-Ares LG (2012) Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study. J Clin Oncol 30: Abstract 7542.
-
(2012)
J Clin Oncol
, vol.30
-
-
Buges, C.1
Marti, A.M.2
Rosell, R.3
Vergnenegre, A.4
De Marinis, F.5
Massuti, B.6
De Castro, J.7
Gervais, R.8
Costa, E.C.9
Moran, T.10
Santarpia, M.11
Felip, E.12
Majem, M.13
Porta, R.14
Palmero, R.15
Drozdowskyj, A.16
Heidecke, C.17
Gasco, A.18
Taron, M.19
Paz-Ares, L.G.20
more..
-
5
-
-
43549094700
-
New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways
-
Burris H 3rd, Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13: 289-298.
-
(2008)
Oncologist
, vol.13
, pp. 289-298
-
-
Burris, H.1
Rocha-Lima, C.2
-
6
-
-
0345205996
-
Rash severity is predictive of increased survival with erlotinib HCl
-
Abstract 786
-
Clark GM, Perez-Soler R, Sui L, Gordon A, Santabarbara P (2003) Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 22: Abstract 786.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Clark, G.M.1
Perez-Soler, R.2
Sui, L.3
Gordon, A.4
Santabarbara, P.5
-
7
-
-
79955921754
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
-
(2011)
N Engl J Med
, vol.364
, pp. 1817-1825
-
-
Conroy, T.1
Desseigne, F.2
Ychou, M.3
Bouche, O.4
Guimbaud, R.5
Becouarn, Y.6
Adenis, A.7
Raoul, J.L.8
Gourgou-Bourgade, S.9
De La Fouchardiere, C.10
Bennouna, J.11
Bachet, J.B.12
Khemissa-Akouz, F.13
Pere-Verge, D.14
Delbaldo, C.15
Assenat, E.16
Chauffert, B.17
Michel, P.18
Montoto-Grillot, C.19
Ducreux, M.20
more..
-
8
-
-
78650095716
-
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3
-
da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS (2010) Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116: 5599-5607.
-
(2010)
Cancer
, vol.116
, pp. 5599-5607
-
-
Da Cunha Santos, G.1
Dhani, N.2
Tu, D.3
Chin, K.4
Ludkovski, O.5
Kamel-Reid, S.6
Squire, J.7
Parulekar, W.8
Moore, M.J.9
Tsao, M.S.10
-
9
-
-
77954216241
-
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
-
Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG (2010) Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 46: 2010-2019.
-
(2010)
Eur J Cancer
, vol.46
, pp. 2010-2019
-
-
Guttman-Yassky, E.1
Mita, A.2
De Jonge, M.3
Matthews, L.4
McCarthy, S.5
Iwata, K.K.6
Verweij, J.7
Rowinsky, E.K.8
Krueger, J.G.9
-
10
-
-
77954786770
-
First-line treatment of metastatic pancreatic adenocarcinoma: Can we do better?
-
Merl MY, Abdelghany O, Li J, Saif MW (2010) First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? JOP 11: 317-320.
-
(2010)
JOP
, vol.11
, pp. 317-320
-
-
Merl, M.Y.1
Abdelghany, O.2
Li, J.3
Saif, M.W.4
-
11
-
-
80053278339
-
Erlotinib 'dosing-torash': A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
-
Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK (2011) Erlotinib 'dosing-torash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 105: 938-944.
-
(2011)
Br J Cancer
, vol.105
, pp. 938-944
-
-
Mita, A.C.1
Papadopoulos, K.2
De Jonge, M.J.3
Schwartz, G.4
Verweij, J.5
Mita, M.M.6
Ricart, A.7
Chu, Q.S.8
Tolcher, A.W.9
Wood, L.10
McCarthy, S.11
Hamilton, M.12
Iwata, K.13
Wacker, B.14
Witt, K.15
Rowinsky, E.K.16
-
12
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine along in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Trials Group
-
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine along in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Trials Group. J Clin Oncol 25: 1960-1966.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Figer, A.4
Hecht, J.R.5
Gallinger, S.6
Au, H.J.7
Murawa, P.8
Walde, D.9
Wolff, R.A.10
Campos, D.11
Lim, R.12
Ding, K.13
Clark, G.14
Voskoglou-Nomikos, T.15
Ptasynski, M.16
Parulekar, W.17
-
13
-
-
63449142391
-
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
-
Peeters M, Siena S, Van Custem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115: 1544-1554.
-
(2009)
Cancer
, vol.115
, pp. 1544-1554
-
-
Peeters, M.1
Siena, S.2
Van Custem, E.3
Sobrero, A.4
Hendlisz, A.5
Cascinu, S.6
Kalofonos, H.7
Devercelli, G.8
Wolf, M.9
Amado, R.G.10
-
14
-
-
84921349038
-
Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: Time course and correlation with survival
-
Abstract 7573
-
Perez-Soler R, Leon L, Wojtowicz-Praga S (2012) Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: time course and correlation with survival. J Clin Oncol 30: Abstract 7573.
-
(2012)
J Clin Oncol
, vol.30
-
-
Perez-Soler, R.1
Leon, L.2
Wojtowicz-Praga, S.3
-
15
-
-
36549083856
-
Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study
-
Abstract LBA4509
-
Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25: Abstract LBA4509.
-
(2007)
J Clin Oncol
, vol.25
-
-
Philip, P.A.1
Benedetti, J.2
Fenoglio-Preiser, C.3
Zalupski, M.4
Lenz, H.5
O'reilly, E.6
Wong, R.7
Atkins, J.8
Abruzzese, J.9
Blanke, C.10
-
16
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
Vergnenegre, A.4
Massuti, B.5
Felip, E.6
Palmero, R.7
Garcia-Gomez, R.8
Pallares, C.9
Sanchez, J.M.10
Porta, R.11
Cobo, M.12
Garrido, P.13
Longo, F.14
Moran, T.15
Insa, A.16
De Marinis, F.17
Corre, R.18
Bover, I.19
Illiano, A.20
Dansin, E.21
De Castro, J.22
Milella, M.23
Reguart, N.24
Altavilla, G.25
Jimenez, U.26
Provencio, M.27
Moreno, M.A.28
Terrasa, J.29
Munoz-Langa, J.30
Valdivia, J.31
Isla, D.32
Domine, M.33
Molinier, O.34
Mazieres, J.35
Baize, N.36
Garcia-Campelo, R.37
Robinet, G.38
Rodriguez-Abreu, D.39
Lopez-Vivanco, G.40
Gebbia, V.41
Ferrera-Delgado, L.42
Bombaron, P.43
Bernabe, R.44
Bearz, A.45
Artal, A.46
Cortesi, E.47
Rolfo, C.48
Sanchez-Ronco, M.49
Drozdowskyj, A.50
Queralt, C.51
De Aguirre, I.52
Ramirez, J.L.53
Sanchez, J.J.54
Molina, M.A.55
Taron, M.56
Paz-Ares, L.57
more..
-
17
-
-
45749152254
-
Erlotinib-induced skin rash
-
Saif MW, Kerikas I, Tsmiboukis S, Syrigos K (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9: 267-274.
-
(2008)
Pathogenesis, Clinical Significance and Management in Pancreatic Cancer Patients. JOP
, vol.9
, pp. 267-274
-
-
Saif, M.W.1
Kerikas, I.2
Tsmiboukis, S.3
Syrigos, K.4
-
18
-
-
0344773402
-
The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies
-
Abstract 817
-
Saltz L, Kies M, Abbruzzese L, Needle M (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22: Abstract 817.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Saltz, L.1
Kies, M.2
Abbruzzese, L.3
Needle, M.4
-
19
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
Tan, E.H.4
Hirsh, V.5
Thongprasert, S.6
Campos, D.7
Maoleekoonpiroj, S.8
Smylie, M.9
Martins, R.10
Van Kooten, M.11
Dediu, M.12
Findlay, B.13
Tu, D.14
Johnston, D.15
Bezjak, A.16
Clark, G.17
Santabarbara, P.18
Seymour, L.19
-
20
-
-
84872063359
-
The association of rash severity with overall survival: Findings from patients receiving erlotinib for pancreatic cancer in the community setting
-
Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Houts AC, Schwartzberg LS (2013) The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas 42: 32-36.
-
(2013)
Pancreas
, vol.42
, pp. 32-36
-
-
Stepanski, E.J.1
Reyes, C.2
Walker, M.S.3
Satram-Hoang, S.4
Leon, L.5
Wojtowicz-Praga, S.6
Miller, P.J.7
Houts, A.C.8
Schwartzberg, L.S.9
-
21
-
-
4143128359
-
Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis
-
Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 11: 305-309.
-
(2003)
Int J Mol Med
, vol.11
, pp. 305-309
-
-
Tobita, K.1
Kijima, H.2
Dowaki, S.3
Kashiwagi, H.4
Ohtani, Y.5
Oida, Y.6
Yamazaki, H.7
Nakamura, M.8
Ueyama, Y.9
Tanaka, M.10
Inokuchi, S.11
Makuuchi, H.12
-
22
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009a) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2231-2237
-
-
Van Cutsem, E.1
Vervenne, W.L.2
Bennouna, J.3
Humblet, Y.4
Gill, S.5
Van Laethem, J.L.6
Verslype, C.7
Scheithauer, W.8
Shang, A.9
Cosaert, J.10
Moore, M.J.11
-
23
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009b) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Eng J Med 360: 1408-1417.
-
(2009)
New Eng J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Kohne, C.H.2
Hitre, E.3
Zaluski, J.4
Chang Chien, C.R.5
Makhson, A.6
D'haens, G.7
Pinter, T.8
Lim, R.9
Bodoky, G.10
Roh, J.K.11
Folprecht, G.12
Ruff, P.13
Stroh, C.14
Tejpar, S.15
Schlichting, M.16
Nippgen, J.17
Rougier, P.18
-
24
-
-
84865092896
-
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study
-
Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30: 2861-2868.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2861-2868
-
-
Van Cutsem, E.1
Tejpar, S.2
Vanbeckevoort, D.3
Peeters, M.4
Humblet, Y.5
Gelderblom, H.6
Vermorken, J.B.7
Viret, F.8
Glimelius, B.9
Gallerani, E.10
Hendlisz, A.11
Cats, A.12
Moehler, M.13
Sagaert, X.14
Vlassak, S.15
Schlichting, M.16
Ciardiello, F.17
-
25
-
-
77249151146
-
Rash as a marker for efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA study
-
Abstract 4532
-
Verslype C, Vervenne W, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E (2009) Rash as a marker for efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. J Clin Oncol 27: Abstract 4532.
-
(2009)
J Clin Oncol
, vol.27
-
-
Verslype, C.1
Vervenne, W.2
Bennouna, J.3
Humblet, Y.4
Cosaert, J.5
Van Cutsem, E.6
-
26
-
-
34447129570
-
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
-
Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13: 3913-3921.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3913-3921
-
-
Wacker, B.1
Nagrani, T.2
Weinberg, J.3
Witt, K.4
Clark, G.5
Cagnoni, P.J.6
-
27
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
Feng, J.4
Liu, X.Q.5
Wang, C.6
Zhang, S.7
Wang, J.8
Zhou, S.9
Ren, S.10
Lu, S.11
Zhang, L.12
Hu, C.13
Hu, C.14
Luo, Y.15
Chen, L.16
Ye, M.17
Huang, J.18
Zhi, X.19
Zhang, Y.20
Xiu, Q.21
Ma, J.22
Zhang, L.23
You, C.24
more..
|